Malignant hyperthermia susceptibility revealed by myalgia and rhabdomyolysis during fluoroquinolone treatment.
Fluoroquinolones cause myalgia, but this complication is not clearly documented. We describe a patient who developed myalgia and rhabdomyolysis during fluoroquinolone treatment. The patient was a 33-year-old man treated with norfloxacin for common cystitis. He complained of general muscular fatigue, tendon disorders, and articular pain during treatment. When the antimicrobial agent was stopped, symptoms decreased, with persistence of slight myalgia for 10 days. Rhabdomyolysis was detected. Six months later, investigation by 31P magnetic resonance spectroscopy revealed an oxidative disorder and an abnormal abundance of phosphomonoesters. In vitro contracture tests led to a diagnosis of malignant hyperthermia susceptibility. Our case shows that for any subject presenting myalgia with rhabdomyolysis triggered by fluoroquinolone treatment, the presence of a latent myopathy should be investigated.
Guis
S
S
Centre de Résonance Magnétique Biologique et Médicale, UMR CNRS 6612, Faculté de Médecine, France.
Jouglard
J
J
Kozak-Ribbens
G
G
Figarella-Branger
D
D
Vanuxem
D
D
Pellissier
J F
JF
Cozzone
P J
PJ
D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D004198:Disease Susceptibility; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis*; D009135:Muscular Diseases / Q000139:chemically induced / Q000175:diagnosis; D009643:Norfloxacin / Q000009:adverse effects*; D010146:Pain / Q000139:chemically induced* / Q000175:diagnosis; D011237:Predictive Value of Tests; D012206:Rhabdomyolysis / Q000139:chemically induced* / Q000175:diagnosis
D000890:Anti-Infective Agents; D009643:Norfloxacin